Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-06
1998-11-17
Ford, John M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514316, 514318, 544357, 544359, 544360, 546186, 546187, C07D40112, C07D40106, C07D40312, C07D40306
Patent
active
058377077
ABSTRACT:
This subject invention relates to dimeric 4-phenylpiperidine, 4-phenyl-1,2,3,6-tetrahydropyridine, or 4-phenylpiperazine compounds or dimeric spirocyclic piperidine compounds having general formula (I), ##STR1## wherein n is 1-5; R.sup.1 to R.sup.4 are substituents; R.sup.5 and R.sup.6 each hydrogen or alkyl or form together an ethylene or propylene bridge; X is O, S, SO, SO.sub.2, CO or (CH.sub.2).sub.m, m being 0 or 1, X is NR.sup.7, R.sup.7 being H, alkyl, cycloalkyl, cycloalkylalkyl, phenyl, or phenylalkyl, or X is CR.sup.8 R.sup.9, wherein R.sup.8 and R.sup.9 are selected from hydroxy and the substituents defined under R.sup.7 ; and (i) Z.sup.1 is a substituent and Z.sup.2 is (CH.sub.2).sub.p wherein p is 0; and Y is N, C or CH; (ii) Z.sup.1 and Y are linked together via a single bond, thereby forming a spirocyclic junction; in which case Y is C; Z.sup.1 is O, S, (CH.sub.2).sub.q, q being 1, 2 or 3, or Z.sup.1 is CH.sub.2 O, CH.sub.2 S, CH.sub.2 CH.sub.2 O, CH.sub.2 CH.sub.2 S, CH.dbd.CH, CH.dbd.CHCH.sub.2, CH.sub.2 OCH.sub.2, CH.sub.2 SCH.sub.2, CH.dbd.CH--O, or CH.dbd.CH--S; and Z.sup.2 is O, S or (CH.sub.2).sub.p, p being 0 or 1; are potent sigma receptor ligands thus being useful as drugs for the treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebrovascular diseases, senile demential of the Alzheimer type or Parkinson's disease.
REFERENCES:
patent: 2891066 (1959-06-01), Parcell
patent: 3408356 (1968-10-01), Horovitz
patent: 3476760 (1969-11-01), Kaiser et al.
patent: 3558637 (1971-01-01), Kaiser et al.
patent: 3686186 (1972-08-01), Houlihan et al.
patent: 3745165 (1973-07-01), Houlihan et al.
patent: 3962259 (1976-06-01), Bauer et al.
patent: 3980658 (1976-09-01), Possanza et al.
patent: 3985889 (1976-10-01), Bauer et al.
patent: 3996211 (1976-12-01), Lassen
patent: 4038395 (1977-07-01), Lassen
patent: 4208417 (1980-06-01), Uzan et al.
patent: 4420485 (1983-12-01), Davis et al.
patent: 4443448 (1984-04-01), B.o slashed.ges.o slashed. 424250
Bally et al. (1887) Chem. Ber., vol. 20, p. 2590.
Barry et al. (1987), "Withdrawal Syndrome Following Subchronic Treatment with Anxiolytic Agents", Pharmac. Biochem. Behav., vol. 27, pp. 239-245.
B.o slashed.ges.o slashed., K. P. et al. (1985), "3-Phenyl-1-indanamines. Potential Antidepressant Activity and Potent Inhibition of Dopamine, Norepinephrine, and Serotonin Uptake", J. Med. Chem., vol. 28, pp. 1817-1828.
B.o slashed.ges.o slashed., K. P. (1983), "Neuroleptic Activity and Dopamine-Uptake Inhibition in 1-Piperazino-3-phenylindans", J. Med. Chem., vol. 26, pp. 935-947.
Hyttel, J. et al. (1985), "Neurochemical Profile of Lu 19-005, a Potent Inhibitor of Uptake of Dopamine, Noradrenaline, and Serotonin", J. Neurochem., vol. 44, pp. 1615-1622.
Allen, R. C. et al. (1978), "Synthesis of System Agents. 4. Central Nervous System Depressants", J. Med. Chem., vol. 21, No. 11, pp. 1149-1154.
Perregaard et al. (1992), "Noncataleptogenic, Centrally Acting Dopamine D-2 and Serotonin 5-HT.sub.2 Antagonists within a Series of 3-Substituted 1-(4-Flurophenyl)-1H-Indoles", J. Med. Chem., vol. 35, pp. 1092-1101.
Martin et al. (1989), "Activity of Aromatic Substituted Phenylpiperazines Lacking Affinity for Dopamine Binding Sites in a Preclinical Test of Antipsychotic Efficacy", J. Med. Chem., vol. 32, pp. 1052-1056.
Marxer et al. (1975), "Spiro Piperidines. I. Synthesis of pp. 1427-1433.
McElvain, S. M. et al. (1950), "Piperidine Derivatives, XXIII. Certain Halogenated 1-Methyl-4-Phenylpiperidines and Related Compounds", J. Amer. Chem. Soc., vol. 72, pp. 3134-3138.
McMillen, B. A. et al. (1988), "N-Alkyl-Substituted Aryl-Piperazine Drugs: Relationship Between Affinity for Serotonin Receptors and Inhibition of Aggression", Drug Develop. Res., vol. 12, pp. 53-62.
Rao, T. S. et al. (1990), "Inhibition of Climbing and Mossy Fiber, and Basket and Stellate Cell Inputs to Mouse Cerebellar Purkinje Cells by Novel Anti-Ischemic Agents, Ifenprodil and BMY-14802", Life Sciences, vol. 47, pp. PL-1--PL-5.
Sanchez et al. (1991), "Neurochemical and In Vivo Pharmacological Profile of Sertindole, a Limbic-Selective Neuroleptic Compound", Drug Deve. Res., vol. 22, pp. 239-250.
Schweizer, E. et al. (1986), "Failure of Buspirone to Manage Benzodiazepine Withdrawal", Am. J. Psychiat., vol. 143, No. 12, pp. 1590-1592.
Skarsfeldt, T. et al. (1990), "Sertindole, A New Neuroleptic with Extreme Selectivity on A10 Versus A9 Dopamine Neurones in the Rat", Eur. J. Pharmacol., vol. 182, pp. 613-614.
Yamato, M. et al. (1981), "Synthesis and Structure-Activity Relationship of Chem. Pharm. Bull., vol. 29, No. 12, pp. 3494-3498.
Yamato, M. et al. (1981), "Synthesis and Structure-Activity Relationship of Release", J. Med. Chem., vol. 24, pp. 194-198.
Chambers, M. S. et al. (1992), "Spiropiperidines as High-Affinity, Selective .alpha. Ligands", J. Med. Chem., vol. 35, pp. 2033-2039.
Rao, Tadimenti S. et al. (1990), "BMY-14802 Antagonizes Harmaline'and D-Serine-Induced Increases in Mouse Cerebellar Cyclic GMP: Neurochemical Evidence for a .sigma. Receptor-Mediated Functional Modulation of Responses Mediated by the N-Methyl-D-aspartate Receptor Complex In Vivo", Molecular Pharmacology, vol. 37, pp. 978-982.
Walker, J.M. et al. (1990) Pharmacological Reviews, vol. 42, p. 355.
Earley et al. (1991) Brain Research, vol. 546, pp. 281-286.
Hyttel, J. (1987), "Age Related Decrease in the Density of Dopamine D.sub.1 and D.sub.2 Receptors in Corpus Striatum of Rats", Pharmacology and Toxicology, vol. 61, pp. 126-129.
Hyttel, J. et al. (1988), "Neurochemical Profile In Vitro of Irindalone: A 5-HT.sub.2 -Receptor Antagonist", Drug Dev. Res., vol. 15, pp. 389-404. H!Acetylcholine Release from Rat Hippocampal Slices", Eur. J. Pharm., vol. 200, pp. 343-345.
Matsuno et al. (1992), "Increase of Extracellular Acetylcholine Level in Rat Frontal Cortex Induced by (+)N-allynormetazocine as Measured by Brain Microdialysis", Brain Research, vol. 545, pp. 315-319.
Parham et al. (1976), J. Org. Chem., vol. 41, p. 2628.
Skarsfeldt, T. et al. (1986), "The St 587-Induced Flexor Reflex in Pithed Rats: A Model to Evaluate Central .alpha..sub.1 -Receptor Blocking Properties", Eur. J. Pharmacol., vol. 125, pp. 333-340.
Van der Weide, J. et al. (1987), "In Vitro Binding of the Very Potent and Membranes", Eur. J. Pharmacol., vol. 134, pp. 211-219. Ligand that Labels .alpha.-type Receptors for Psychotomimetic Opiates and Antipsychotic Drugs", Proc. Natl. Acad. Sci., vol. 83, pp. 8784-8788.
Snyder, S.H. et al. (1989), "Receptor Mechanisms in Antipsychotic Drug Action: Focus on Sigma Receptors," Neuropsychiatry, vol. 1, p. 7.
Colpaert, F.C. et al. (1985), Psychopharmacology, vol. 86, pp. 303-305.
Moltzen Ejner K.
Perregaard Jens
Stenberg John W.
Ford John M.
H. Lundbeck A/S
Kifle Bruck
LandOfFree
Dimeric piperidine, tetrahydropyridine and piperazine derivative does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dimeric piperidine, tetrahydropyridine and piperazine derivative, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dimeric piperidine, tetrahydropyridine and piperazine derivative will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-884666